Skip to main content
SpringerLink
Log in

Histopathologic Features and Prognostic Factors

  • Chapter
  • First Online:
Clinical Ophthalmic Oncology

Abstract

Retinoblastoma is a tumor that arises from the neuroblastic cells that comprise the nuclear layers of the retina. Grossly, the tumor is classified by its pattern of growth into endophytic, exophytic, mixed, diffuse infiltrative, and necrotic variants. The characteristic histopathologic findings in retinoblastoma include a tumor that replaces the retina with medium-sized cells that have a high nuclear/cytoplasmic ratio, marked apoptotic and mitotic activity, and foci of necrosis with calcification. If left untreated, retinoblastoma usually fills the eye and completely destroys the internal architecture of the globe. The tumor tends to spread locally by invading the optic nerve and choroid, and then hematogenously, and by lymphatics once it reaches the extraocular structures such as the conjunctiva and eyelids. Multivariate statistical analysis has suggested the correlation of histopathologic findings such as the presence of tumor in the optic nerve posterior to the lamina cribrosa, tumor at the site of surgical transection, and extrascleral extension of tumor into the orbit with risk of metastasis. Other factors associated with probable risk for metastatic behavior, especially in conjunction with the major factors cited above, are massive choroidal invasion, tumor invasion into the anterior chamber, large tumor size with vitreous seeding, neovascularization of the iris, and glaucoma. It is important to analyze the eye appropriately to evaluate the possible high-risk features. Guidelines for handling the eye have been published as a result of a consensus from the International Retinoblastoma Staging Working Group that also includes criteria used in the prospective clinical trial from the Children’s Oncology Group (ARET0332 A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study). Animal models, and histopathological and collaborative clinical trials, will certainly facilitate the understanding of these factors and ultimately allow the use of targeted therapies to prevent metastasis and death from retinoblastoma.​

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. McLean IW, Burnier M, Zimmerman L, et al. Tumors of the retina. In: McLean IW, Burnier MN, Zimmerman LE, et al., editors. Tumors of the eye and ocular adnexa, Atlas of tumor pathology. Washington, DC: Armed Forced Institute of Pathology; 1994. p. s100–35.

    Google Scholar 

  2. Hurwitz RL, Chévez-Barrios P, Chintagumpala M, et al. Retinoblastoma. In: Pizzo PA, Poplack D, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott-Raven; 2006. p. 825–46.

    Google Scholar 

  3. Sang DN, Albert DM. Retinoblastoma: clinical and histopathologic features. Hum Pathol. 1982;13:133–47.

    Article  CAS  Google Scholar 

  4. Augsburger JJ, Oehlschlager U, Manzitti JE. Multinational clinical and pathologic registry of retinoblastoma. Retinoblastoma International Collaborative Study Report 2. Graefes Arch Clin Exp Ophthalmol. 1995;233:469–75.

    Article  CAS  Google Scholar 

  5. Andersen SR, Jensen OA. Retinoblastoma with necrosis of central retinal artery and vein and partial spontaneous regression. Acta Ophthalmol. 1974;52:183–93.

    Article  CAS  Google Scholar 

  6. Mullaney PB, Karcioglu ZA, Huaman AM, et al. Retinoblastoma associated orbital cellulitis. Br J Ophthalmol. 1998;82:517–21.

    Article  CAS  Google Scholar 

  7. Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810–7.

    Article  Google Scholar 

  8. Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015;122(6):1173–9.

    Article  Google Scholar 

  9. Amram AL, Rico G, Kim JW, et al. Vitreous Seeds in Retinoblastoma: Clinicopathologic Classification and Correlation. Ophthalmology. 2017. pii: S0161–6420(17)30285–3. doi: https://doi.org/10.1016/j.ophtha.2017.04.015. [Epub ahead of print] PubMed PMID: 28528011.

  10. Spencer WH. Optic nerve extension of intraocular neoplasms. Am J Ophthalmol. 1975;80:465–71.

    Article  CAS  Google Scholar 

  11. Magramm I, Abramson DH, Ellsworth RM. Optic nerve involvement in retinoblastoma. Ophthalmology. 1989;96:217–22.

    Article  CAS  Google Scholar 

  12. Stannard C, Lipper S, Sealy R, et al. Retinoblastoma: correlation of invasion of the optic nerve and choroid with prognosis and metastases. Br J Ophthalmol. 1979;63:560–70.

    Article  CAS  Google Scholar 

  13. Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73:692–8.

    Article  CAS  Google Scholar 

  14. Rubin CM, Robison LL, Camerson JD, et al. Intraocular retinoblastoma Group V: an analysis of prognostic factors. J Clin Oncol. 1985;3:680–5.

    Article  CAS  Google Scholar 

  15. Khelfaoui F, Validire P, Auperin A, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206–13.

    Article  CAS  Google Scholar 

  16. Chantada GL, de Davila MT, Fandino A, et al. Retinoblastoma with low risk for extraocular relapse. Ophthalmic Genet. 1999;20:133–40.

    Article  CAS  Google Scholar 

  17. Erwenne CM, Franco EL. Age and lateness of referral as determinants of extraocular retinoblastoma. Ophthalmic Paediatr Genet. 1989;10:179–84.

    Article  CAS  Google Scholar 

  18. Rootman J, Ellsworth RM, Hofbauer J, et al. Orbital extension of retinoblastoma: a clinicopathological study. Can J Ophthalmol. 1978;13:72–80.

    CAS  PubMed  Google Scholar 

  19. MacKay CJ, Abramson DH, Ellsworth RM. Metastatic patterns of retinoblastoma. Arch Ophthalmol. 1984;102:391–6.

    Article  CAS  Google Scholar 

  20. Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation. Ophthalmology. 1987;94:371–7.

    Article  CAS  Google Scholar 

  21. de Buen S, Gonzalez-Almaraz G, Cruz-Perez R. Retinoblastoma. Considerations on its biological behavior. Gac Med Mex. 1974;108:177–86.

    PubMed  Google Scholar 

  22. Messmer EP, Heinrich T, Hopping W, et al. Risk factors for metastases in patients with retinoblastoma. Ophthalmology. 1991;98:136–41.

    Article  CAS  Google Scholar 

  23. Karcioglu ZA, al-Mesfer SA, Abboud E, et al. Workup for metastatic retinoblastoma. A review of 261 patients. Ophthalmology. 1997;104:307–12.

    Article  CAS  Google Scholar 

  24. Tosi P, Cintorino M, Toti P, et al. Histopathological evaluation for the prognosis of retinoblastoma. Ophthalmic Paediatr Genet. 1989;10:173–7.

    Article  CAS  Google Scholar 

  25. Sastre X, Chantada GL, Doz F, et al. International Retinoblastoma Staging Working Group. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009;133(8):1199–202. https://doi.org/10.1043/1543-2165-133.8.1199.

  26. Marback EF, Arias VE, Paranhos A Jr, et al. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol. 2003;87:1224–8.

    Article  Google Scholar 

  27. Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119:41–8.

    Article  CAS  Google Scholar 

  28. Redler LD, Ellsworth RM. Prognostic importance of choroidal invasion in retinoblastoma. Arch Ophthalmol. 1973;90:294–6.

    Article  CAS  Google Scholar 

  29. Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2000;37:134–41.

    CAS  PubMed  Google Scholar 

  30. Romani AA, Borghetti AF, Del Rio P, et al. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol. 2006;93:446–55.

    Article  Google Scholar 

  31. Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res. 2006;66:3303–9.

    Article  CAS  Google Scholar 

  32. Shields CL, Shields JA, Baez KA, et al. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol. 1993;77:544–8.

    Article  CAS  Google Scholar 

  33. Chong EM, Coffee RE, Chintagumpala M, et al. Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med. 2006;130(11):1669–72.

    PubMed  Google Scholar 

  34. Demirci H, Eagle RC Jr, Shields CL, et al. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol. 2003;121(8):1125–31.

    Article  Google Scholar 

  35. Ts’o MO, Zimmerman LE, Fine BS, et al. A cause of radioresistance in retinoblastoma: photoreceptor differentiation. Trans Am Acad Ophthalmol Otolaryngol. 1970;74:959–69.

    PubMed  Google Scholar 

  36. Eagle RC Jr, Shields CL, Bianciotto C, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol. 2011;129(11):1416–21.

    Article  Google Scholar 

  37. Munier FL, Beck-Popovic M, Balmer A, et al. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31(3):566–73.

    Article  CAS  Google Scholar 

  38. Wilson MW, Jackson JS, Philips BX, et al. Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Opthalmol. 2011;129(11):1458–65.

    Article  CAS  Google Scholar 

  39. Fallaha N, Dubois J, Carret AS, et al. Real-time ophthalmoscopic findings of intraophthalmic artery chemotherapy in retinoblastoma. Arch Ophthalmol. 2012;130(8):1075–7.

    Article  Google Scholar 

  40. Kaliki S, Shields CL, Shah SU, et al. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011;129(11):1422–7.

    Article  CAS  Google Scholar 

  41. Vajzovic LM, Murray TG, Aziz-Sultan MA, et al. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. Arch Ophthalmol. 2010;128(12):1619–23.

    Article  Google Scholar 

  42. Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133(8):1203–9.

    PubMed  Google Scholar 

  43. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer. 1996;32A:2451–60.

    Article  CAS  Google Scholar 

  44. Chevez-Barrios P, Hurwitz MY, Louie K, et al. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol. 2000;157:1405–12.

    Article  CAS  Google Scholar 

  45. Burnier MN, McLean IW, Zimmerman LE, et al. The relationship of proliferating cells to blood vessels. Invest Ophthalmol Vis Sci. 1990;31:2037–40.

    CAS  PubMed  Google Scholar 

  46. O’Byrne KJ, Dalgleish AG, Browning MJ, et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 2000;36:151–69.

    Article  Google Scholar 

  47. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21:497–503.

    Article  CAS  Google Scholar 

  48. Garcia JR, Gombos DS, Prospero CM, et al. Expression of Angiogenic Factors in Invasive Retinoblastoma Tumors Is Associated With Increase in Tumor Cells Expressing Stem Cell Marker Sox2. Arch Pathol Lab Med. 2015 Dec;139(12):1531–8. https://doi.org/10.5858/arpa.2014-0262-OA.

    Article  CAS  PubMed  Google Scholar 

  49. Honavar SG, Singh AD, Shields CL, et al. Does post-enucleation prophylactic chemotherapy in high risk retinoblastoma prevent metastasis? Invest Ophthalmol Vis Sci. 2000;41:S953.

    Google Scholar 

  50. Mustafa MM, Jamshed A, Khafaga Y, et al. Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. J Pediatr Hematol Oncol. 1999;21:364–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology and Genomic Medicine and Ophthalmology, Weill Cornell Medical College, New York, NY, USA

    Patricia Chévez-Barrios

  2. Houston Methodist Hospital, Houston, TX, USA

    Patricia Chévez-Barrios

  3. Department of Pathology, Wills Eye Hospital Thomas Jefferson University, Philadelphia, PA, USA

    Ralph C. Eagle

  4. Department of Ophthalmology, Federal University of Bahia, Rio Vermelho, Salvador, Bahia, Brazil

    Eduardo F. Marback

Authors
  1. Patricia Chévez-Barrios
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph C. Eagle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eduardo F. Marback
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia Chévez-Barrios .

Editor information

Editors and Affiliations

  1. Associate Professor of Ophthalmology, Children’s Hospital Los Angeles, The USC Roski Eye Institute Keck School of Medicine, Los Angeles, CA, USA

    Jesse L. Berry

  2. Children’s Hospital Los Angeles, The USC Roski Eye Institute, Keck School of Medicine, Los Angeles, CA, USA

    Jonathan W. Kim

  3. University of Oxford, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK

    Bertil E. Damato

  4. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

    Arun D. Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chévez-Barrios, P., Eagle, R.C., Marback, E.F. (2019). Histopathologic Features and Prognostic Factors. In: Berry, J., Kim, J., Damato, B., Singh, A. (eds) Clinical Ophthalmic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-11123-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11123-6_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11122-9

  • Online ISBN: 978-3-030-11123-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation